Avaliação da incidência de rejeição aguda em uma coorte retrospectiva de pacientes retransplantados renais submetidos a regimes de indução com timoglobulina 3mg/kg versus 5mg/kg: análise comparativa

Abstract

Optimizing antithymocyte globulin (rATG) dosage is critical for high immunological risk patients undergoing a repeat kidney transplant. This natural retrospective cohort study compared clinical outcomes of two successive cohorts of consecutive recipients of retransplants receiving 5 x 1 mg/kg (rATG- 5, n=100) or a single 3 mg/kg (rATG-3, n=110) dose of rATG induction therapy. All patients had negative complement-dependent cytotoxicity crossmatch and no anti-HLA A, B, DR donor-specific antibodies (DSA). The primary endpoint was efficacy failure (first biopsy-proven acute rejection, graft loss, or death) at 12 months. There was no difference in the cumulative incidence of efficacy failure (18.0% vs. 21.8%, HR=1.22, 95% CI 0.66 - 2.25), respectively. There were no differences in 3-years freedom from biopsy proven acute rejection, and patient, graft, and death-censored graft survivals.